|
|
|
|
|
|
|
|
|
|
|
 
|
Pancreas Cancer
News and Archives |
|
 |
For educational purposes only; not to be relied upon. Please read Pancreatica Disclaimer | |
| December 30, 2002 | SuperGen Submits First Module of Orathecin's(TM) 'Rolling' New Drug Application as an Oral Treatment for Pancreatic Cancer | |
| December 19, 2002 | Aphton Announces Australia Grants Orphan-Drug Designation for its Anti-Gastrin Immunogen G17DT for Treatment of Both Gastric Cancer and Pancreatic Cancer | |
| December 18, 2002 | Isis Pharmaceuticals Reports New Data From Phase II Clinical Trial Of ISIS 2503 Plus Chemotherapy in Pancreatic Cancer | |
| December 15, 2002 | Clinical Characteristics and Outcomes from an Institutional Series of Acinar Cell Carcinoma of the Pancreas and Related Tumors | |
| December 15, 2002 | VEGF-RII Influences the Prognosis of Pancreatic Cancer | |
| December 6, 2002 | Gene Therapy Fights Pancreatic Cancer in Mice | |
| December 1, 2002 | A Phase-II Study of Liposomal Doxorubicin and Docetaxel in Patients with Advanced Pancreatic Cancer | |
| December 1, 2002 | Challenging Pancreatic Cancer-Prone Pedigrees: A Nosologic Dilemma | |
| December 1, 2002 | Concurrent Resections of Pancreatic Islet Cell Cancers with Synchronous Hepatic Metastases: Outcomes of an Aggressive Approach | |
| December 1, 2002 | DPC4/Smad4 Expression and Outcome in Pancreatic Ductal Adenocarcinoma | |
| December 1, 2002 | Inflammation and the Development of Pancreatic Cancer | |
| December 1, 2002 | Local Staging of Pancreatic Carcinoma with Multi-Detector Row CT: Use of Curved Planar Reformations Initial Experience | |
| December 1, 2002 | Localization of Gastrinomas by Selective Intra-Arterial Calcium Injection | |
| December 1, 2002 | Mucin Gene (MUC1) Transfected Dendritic Cells as Vaccine: Results of a Phase I/II Clinical Trial | |
| December 1, 2002 | National Estimates of Mortality Rates for Radical Pancreaticoduodenectomy in 25,000 Patients | |
| December 1, 2002 | Pancreatic Cancer: Epidemiology, Genetics, and Approaches to Screening | |
| December 1, 2002 | Predictive Factors Associated With Long-Term Survival in Patients With Neuroendocrine Tumors of the Pancreas | |
| December 1, 2002 | Prognostic Implications of Routine, Immunohistochemical, and Molecular Staging in Resectable Pancreatic Adenocarcinoma | |
| December 1, 2002 | Regional Targeting Chemoimmunotherapy in Patients Undergoing Pancreatic Resection in an Advanced Stage of Their Disease: A Prospective Randomized Study | |
| December 1, 2002 | Selective Cyclooxygenase-2 Inhibitor Rofecoxib (Vioxx) Induces Expression of Cell Cycle Arrest Genes and Slows Tumor Growth in Human Pancreatic Cancer | |
| December 1, 2002 | Smoking Cessation Would Substantially Reduce the Future Incidence of Pancreatic Cancer in the European Union | |
| November 20, 2002 | Onyx Updates Phase I Data for BAY 43-9006 at 2002 EORTC-NCI-AACR Meeting in Frankfurt | |
| November 15, 2002 | Management of Advanced Pancreatic Cancer: Staging Laparoscopy and Immunochemotherapy--A New Treatment Strategy | |
| November 15, 2002 | Treatment of Pancreatic Cancer Xenografts with Erbitux (IMC-C225) Anti-EGFR Antibody, Gemcitabine, and Radiation | |
| November 11, 2002 | SuperGen's New Drug Application (NDA) for Orathecin(TM) Granted 'Fast-Track' Designation by FDA | |
| November 7, 2002 | Treatment of Cancer Patients with Virulizin(R) Through Lorus Therapeutics' Emergency Drug Program | |
| November 1, 2002 | A Case of Pancreatic Tail Cancer with Peritoneal Carcinosis Treated with Gemcitabine Hydrochloride | |
| November 1, 2002 | A Prospective Study of Detection of Pancreatic Carcinoma by Combined Plasma K-ras Mutations and Serum CA19-9 Analysis | |
| November 1, 2002 | Differentiation of Pancreatic Tumours by Conventional Ultrasound, Unenhanced and Echo-enhanced Power Doppler Sonography | |
| November 1, 2002 | High Response Rates in Patients with Pancreatic Cancer Using the Novel Oral Fluoropyrimidine S-1 | |
| November 1, 2002 | Intra-arterial Chemotherapy with Gemcitabine (GEM) for Unresectable Pancreatic Cancer | |
| November 1, 2002 | Intraoperative Radiotherapy (IORT) for Unresectable Stage IVb Pancreatic Cancer | |
| November 1, 2002 | Interferon-gamma Inhibits Growth of Human Neuroendocrine Carcinoma Cells Via Induction of Apoptosis | |
| November 1, 2002 | Locoregional Chemotherapy for Patients with Pancreatic Cancer Intra-arterial Adjuvant Chemotherapy After Pancreatectomy with Portal Vein Resection | |
| November 1, 2002 | New Drugs for Patients with Pancreatic Cancer | |
| November 1, 2002 | Patients with Non-advanced Pancreatic Cancer Benefit from Extended Lymphadenectomy | |
| November 1, 2002 | Periampullary Pancreatic Somatostatinoma | |
| November 1, 2002 | Phase I Pharmacodynamic Study of Time and Sequence Dependency of Hydroxyurea in Combination with Gemcitabine: A California Cancer Consortium Trial | |
| November 1, 2002 | Phase I Study of Weekly Gemcitabine as a Radiation Sensitizer for Unresectable Pancreatic Cancer | |
| November 1, 2002 | Phase II Study of Gemcitabine Combined With Radiation Therapy in Patients With Localized, Unresectable Pancreatic Cancer | |
| November 1, 2002 | Prognosis of Malignant Intraductal Papillary Mucinous Tumours of the Pancreas after Surgical Resection. Comparison with Pancreatic Ductal Adenocarcinoma | |
| November 1, 2002 | Telomere Shortening is Nearly Universal in Pancreatic Intraepithelial Neoplasia | |
| November 1, 2002 | The Stem Cell Factor-C-Kit System and Mast Cells in Human Pancreatic Cancer | |
| November 1, 2002 | The Value of Standard Serum Tumor Markers in Differentiating Mucinous from Serous Cystic Tumors of the Pancreas: CEA, Ca 19-9, Ca 125, Ca 15-3 | |
| November 1, 2002 | Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma with Combined Radiochemotherapy with 5-Fluorouracil and Cisplatin | |
| November 1, 2002 | Usefulness of CT Arteriography for Transcatheter Peripancreatic Arterial Embolization to Patients with Advanced Pancreatic Cancer | |
| October 31, 2002 | Clinical Outcome of Simultaneous Self-Expandable Metal Stents for Palliation of Malignant Biliary and Duodenal Obstruction | |
| October 31, 2002 | Role of Self-Expandable Metal Stents in the Palliation of Malignant Duodenal Obstruction | |
| October 31, 2002 | SuperGen Targets Submission of New Drug Application for Orathecin(TM) by Year-End After Favorable FDA Meeting | |
| October 31, 2002 | GlycoGenesys and Elan Announce GCS-100 Shows Early Signs of Clinical Activity in Phase IIa Pancreatic Cancer Trial | |
| October 29, 2002 | Laparoscopic Body-tail Pancreatic Resection for Insulinoma | |
| October 29, 2002 | Laparoscopic Staging of Pancreatic Tumors Induces Increased Invasive Capacity In Vitro | |
| October 28, 2002 | Aphton Announces 53% Increased Median Survival Time in European Phase III Clinical Trial for Monotherapy Treatment of Pancreatic Cancer With G17DT | |
| October 23, 2002 | Panacea Pharmaceuticals, Inc. Awarded SBIR Grant From National Cancer Institute to Develop Diagnostic Test for Pancreatic Cancer | |
| October 15, 2002 | Phase II Study of Anti-Gastrin-17 Antibodies, Raised to G17DT, in Advanced Pancreatic Cancer | |
| October 15, 2002 | Phase II Trial of 5-fluorouracil Plus Eniluracil in Patients with Advanced Pancreatic Cancer: A Southwest Oncology Group Study | |
| October 14, 2002 | Wilex Initiates First Clinical Trial for Urokinase Inhibitor WX-UK1 in Cancer Patients | |
| October 8, 2002 | Laparoscopic Choledochojejunostomy and Gastrojejunostomy in a Porcine Model | |
| October 7, 2002 | Irinotecan, Cisplatin and Mitomycin in Inoperable Gastro-Oesophageal and Pancreatic Cancers - A New Active Regimen | |
| October 1, 2002 | Antitumorigenic and Antiinsulinogenic Effects of Calcitriol on Insulinoma Cells and Solid Beta-Cell Tumors | |
| October 1, 2002 | Clinical Response of an Atypical Glucagonoma Treated with a Long-acting Somatostatin Analog | |
| October 1, 2002 | Does Neoadjuvant Chemoradiation Downstage Locally Advanced Pancreatic Cancer? | |
| October 1, 2002 | Nonfunctioning Islet Cell Carcinoma of the Pancreas: Case Report | |
| October 1, 2002 | Occlusion of the Pancreatic Duct versus Pancreaticojejunostomy: A Prospective Randomized Trial | |
| October 1, 2002 | Preoperative Endoscopic Stent Placement Before Pancreaticoduodenectomy: A Meta-Analysis of the Effect on Morbidity and Mortality | |
|
SuperGen
Submits First Module of Orathecin's(TM) 'Rolling' New Drug Application
as an Oral Treatment for Pancreatic Cancer SuperGen Inc. announced today that it has begun submission of a New Drug Application (NDA) for its anticancer compound Orathecin(TM), an oral chemotherapy compound in the camptothecin class, for the treatment of pancreatic cancer patients who are refractory (resistant) to available therapies. The submission will occur on a 'rolling' basis and is expected to be completed by the end of the first-quarter of 2003. The first module submitted contained the chemistry, manufacturing and controls (CMC) section. ...full article
Aphton
Announces Australia Grants Orphan-Drug Designation for its Anti-Gastrin
Immunogen G17DT for Treatment of Both Gastric Cancer and Pancreatic
Cancer Aphton Corporation announced today that it received official notice from the Therapeutic Goods Administration (TGA), the regulatory authority in Australia equivalent to the U.S. Food and Drug Administration, granting its anti-gastrin G17DT Immunogen Orphan-Drug status for treatment of both gastric (stomach) cancer and pancreatic cancer. Unlike in the United States, the Australian orphan-drug designation automatically confers priority evaluation for the drug ahead of other evaluations. ...full article
Isis
Pharmaceuticals Reports New Data From Phase II Clinical Trial
Of ISIS 2503 Plus Chemotherapy in Pancreatic Cancer In a Phase II clinical trial of ISIS 2503 in combination with gemcitabine, median survival time was more than six months in patients with pancreatic cancer, exceeding the primary endpoint of the study. Summary results of the Phase II study were described yesterday at the 6th National Institutes of Health Therapeutic Oligonucleotide Interest Group Symposium in Bethesda, Maryland. The North Central Cancer Treatment Group (NCCTG), a North American cancer cooperative group with its research base located at Mayo Clinic in Rochester, Minnesota, designed and conducted the Phase II trial. Mayo Clinic has submitted complete results from the study to the 2003 Annual Meeting of the American Society of Clinical Oncology (ASCO). Based on the findings of this trial, Isis Pharmaceuticals, Inc. is considering various strategies for potential Phase III development of ISIS 2503 in pancreatic cancer. ...full article
Clinical
Characteristics and Outcomes from an Institutional Series of
Acinar Cell Carcinoma of the Pancreas and Related Tumors [Abstract]
VEGF-RII
Influences the Prognosis of Pancreatic Cancer [Abstract]
Gene
Therapy Fights Pancreatic Cancer in Mice Because it is often caught only in its more advanced stages, pancreatic cancer -- the fifth leading cause of cancer death in the US -- is rarely curable. But Japanese researchers are using gene therapy to achieve what they call "dramatic" results in shrinking pancreatic tumors in mice, even after the cancer has spread beyond the pancreas. ...full article
A
Phase-II Study of Liposomal Doxorubicin and Docetaxel in Patients
with Advanced Pancreatic Cancer [Abstract]
Challenging
Pancreatic Cancer-Prone Pedigrees: A Nosologic Dilemma [Abstract]
Concurrent
Resections of Pancreatic Islet Cell Cancers with Synchronous
Hepatic Metastases: Outcomes of an Aggressive Approach [Abstract]
DPC4/Smad4
Expression and Outcome in Pancreatic Ductal Adenocarcinoma [Abstract]
Inflammation
and the Development of Pancreatic Cancer [Abstract]
Local
Staging of Pancreatic Carcinoma with Multi-Detector Row CT: Use
of Curved Planar Reformations Initial Experience [Abstract]
Localization
of Gastrinomas by Selective Intra-Arterial Calcium Injection [Abstract]
Mucin
Gene (MUC1) Transfected Dendritic Cells as Vaccine: Results of
a Phase I/II Clinical Trial [Abstract]
National
Estimates of Mortality Rates for Radical Pancreaticoduodenectomy
in 25,000 Patients [Abstract]
Pancreatic
Cancer: Epidemiology, Genetics, and Approaches to Screening [Abstract]
Predictive
Factors Associated With Long-Term Survival in Patients With Neuroendocrine
Tumors of the Pancreas [Abstract]
Prognostic
Implications of Routine, Immunohistochemical, and Molecular Staging
in Resectable Pancreatic Adenocarcinoma [Abstract]
Regional
Targeting Chemoimmunotherapy in Patients Undergoing Pancreatic
Resection in an Advanced Stage of Their Disease: A Prospective
Randomized Study [Abstract]
Selective
Cyclooxygenase-2 Inhibitor Rofecoxib (Vioxx) Induces Expression
of Cell Cycle Arrest Genes and Slows Tumor Growth in Human Pancreatic
Cancer [Abstract]
Smoking
Cessation Would Substantially Reduce the Future Incidence of
Pancreatic Cancer in the European Union [Abstract]
Onyx
Updates Phase I Data for BAY 43-9006 at 2002 EORTC-NCI-AACR Meeting
in Frankfurt Onyx Pharmaceuticals, Inc. today announced updated Phase I clinical data for BAY 43-9006, a novel anticancer investigational agent. BAY 43-9006 is an orally active small molecule raf kinase inhibitor being co-developed in a collaboration between Onyx and Bayer. The updated data were presented today in Frankfurt, Germany, at the European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) 2002 meeting. ...full article
Management
of Advanced Pancreatic Cancer: Staging Laparoscopy and Immunochemotherapy--A
New Treatment Strategy [Abstract]
Treatment
of Pancreatic Cancer Xenografts with Erbitux (IMC-C225) Anti-EGFR
Antibody, Gemcitabine, and Radiation [Abstract]
SuperGen's
New Drug Application (NDA) for Orathecin(TM) Granted 'Fast-Track'
Designation by FDA SuperGen Inc. announced today that following a favorable meeting with the Food and Drug Administration, the company is on track to begin filing, by year-end, a New Drug Application (NDA) for its anticancer compound Orathecin(TM) (rubitecan), an oral chemotherapy compound in the camptothecin class, for the treatment of pancreatic cancer patients who are refractory (resistant) to available therapies. This will represent the first oral camptothecin submitted to the FDA for approval. ...full article
Treatment
of Cancer Patients with Virulizin(R) Through Lorus Therapeutics'
Emergency Drug Program Lorus Therapeutics Inc. ("Lorus")
today announced that it has renewed an emergency drug program
to supply its anticancer product, Virulizin(R) for the treatment
of advanced pancreatic cancer. The emergency drug program is
available to cancer patients worldwide through their physicians. ...full article
A
Case of Pancreatic Tail Cancer with Peritoneal Carcinosis Treated
with Gemcitabine Hydrochloride [Abstract]
A
Prospective Study of Detection of Pancreatic Carcinoma by Combined
Plasma K-ras Mutations and Serum CA19-9 Analysis [Abstract]
Differentiation
of Pancreatic Tumours by Conventional Ultrasound, Unenhanced
and Echo-enhanced Power Doppler Sonography [Abstract]
High
Response Rates in Patients with Pancreatic Cancer Using the Novel
Oral Fluoropyrimidine S-1 [Abstract]
Intra-arterial
Chemotherapy with Gemcitabine (GEM) for Unresectable Pancreatic
Cancer [Abstract]
Intraoperative
Radiotherapy (IORT) for Unresectable Stage IVb Pancreatic Cancer [Abstract]
Interferon-gamma
Inhibits Growth of Human Neuroendocrine Carcinoma Cells Via Induction
of Apoptosis [Abstract]
Locoregional
Chemotherapy for Patients with Pancreatic Cancer Intra-arterial
Adjuvant Chemotherapy After Pancreatectomy with Portal Vein Resection [Abstract]
New
Drugs for Patients with Pancreatic Cancer [Abstract]
Patients
with Non-advanced Pancreatic Cancer Benefit from Extended Lymphadenectomy [Abstract]
Periampullary
Pancreatic Somatostatinoma [Abstract]
Phase
I Pharmacodynamic Study of Time and Sequence Dependency of Hydroxyurea
in Combination with Gemcitabine: A California Cancer Consortium
Trial [Abstract]
Phase
I Study of Weekly Gemcitabine as a Radiation Sensitizer for Unresectable
Pancreatic Cancer [Abstract]
Phase
II Study of Gemcitabine Combined With Radiation Therapy in Patients
With Localized, Unresectable Pancreatic Cancer [Abstract]
Prognosis
of Malignant Intraductal Papillary Mucinous Tumours of the Pancreas
after Surgical Resection. Comparison with Pancreatic Ductal Adenocarcinoma
[Abstract]
Telomere
Shortening is Nearly Universal in Pancreatic Intraepithelial
Neoplasia [Abstract]
The
Stem Cell Factor-C-Kit System and Mast Cells in Human Pancreatic
Cancer [Abstract]
The
Value of Standard Serum Tumor Markers in Differentiating Mucinous
from Serous Cystic Tumors of the Pancreas: CEA, Ca 19-9, Ca 125,
Ca 15-3 [Abstract]
Treatment
of Unresectable, Locally Advanced Pancreatic Adenocarcinoma with
Combined Radiochemotherapy with 5-Fluorouracil and Cisplatin [Abstract]
Usefulness
of CT Arteriography for Transcatheter Peripancreatic Arterial
Embolization to Patients with Advanced Pancreatic Cancer [Abstract]
Clinical
Outcome of Simultaneous Self-Expandable Metal Stents for Palliation
of Malignant Biliary and Duodenal Obstruction [Abstract]
Role
of Self-Expandable Metal Stents in the Palliation of Malignant
Duodenal Obstruction [Abstract]
SuperGen
Targets Submission of New Drug Application for Orathecin(TM)
by Year-End After Favorable FDA Meeting SuperGen Inc. announced today that following a favorable meeting with the Food and Drug Administration, the company is on track to begin filing, by year-end, a New Drug Application (NDA) for its anticancer compound Orathecin(TM) (rubitecan), an oral chemotherapy compound in the camptothecin class, for the treatment of pancreatic cancer patients who are refractory (resistant) to available therapies. This will represent the first oral camptothecin submitted to the FDA for approval. ...full article
GlycoGenesys
and Elan Announce GCS-100 Shows Early Signs of Clinical Activity
in Phase IIa Pancreatic Cancer Trial GlycoGenesys, Inc., a biotechnology company focused on carbohydrate-based drug development and Elan Corporation, plc, today announced the Phase II(a) clinical trial results from their oncology joint venture. The Phase II(a) clinical trial evaluated patients with refractory or relapsed pancreatic adenocarcinoma (cancer) treated with GCS-100, an experimental cancer drug candidate, at a dose of 20 mg/m2, twice weekly. The clinical trial enrolled 20 patients in an open-label, single-arm program designed to obtain additional data regarding the agent's safety and clinical activity at the 20mg/m2 dose level. As is customary in such clinical trials, patients were taken off GCS-100 if their disease progressed as determined by tumor lesion measurements. ...full article
Laparoscopic
Body-tail Pancreatic Resection for Insulinoma [Abstract]
Laparoscopic
Staging of Pancreatic Tumors Induces Increased Invasive Capacity
In Vitro [Abstract]
Aphton
Announces 53% Increased Median Survival Time in European Phase
III Clinical Trial for Monotherapy Treatment of Pancreatic Cancer
With G17DT Aphton Corporation announced today results of a randomized, double-blind, controlled, statistically powered, phase III clinical trial conducted in European countries. ...full article
Panacea
Pharmaceuticals, Inc. Awarded SBIR Grant From National Cancer
Institute to Develop Diagnostic Test for Pancreatic Cancer Panacea Pharmaceuticals, Inc. announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The grant will provide funding towards the development of a diagnostic test for pancreatic cancer based on the Company's HAAH Oncology Program, which targets the enzyme Human Aspartyl Asparaginyl Beta-Hydroxylase or HAAH as both a therapeutic target and as a cancer marker. ...full article
Phase
II Study of Anti-Gastrin-17 Antibodies, Raised to G17DT, in Advanced
Pancreatic Cancer [Abstract]
Phase
II Trial of 5-fluorouracil Plus Eniluracil in Patients with Advanced
Pancreatic Cancer: A Southwest Oncology Group Study [Abstract]
Wilex
Initiates First Clinical Trial for Urokinase Inhibitor WX-UK1
in Cancer Patients Wilex AG, Munich, today announced the initiation of a phase Ib/IIa clinical trial with WX-UK1, a small molecule inhibitor of the uPA (Urokinase-type plasminogen activator) system which has been shown to play a key role in the progression and metastasis of various solid tumors. The dose escalation study will evaluate tolerability and biological activity of WX-UK1 in patients with advanced gastric, pancreatic and ovarian cancers. The national multicenter trial is being conducted by Prof. Christian Peschel, MD, director of the III. Medical Department at the Technical University of Munich. First preliminary results are expected in second half of 2003. ...full article
Laparoscopic
Choledochojejunostomy and Gastrojejunostomy in a Porcine Model
[Abstract]
Irinotecan,
Cisplatin and Mitomycin in Inoperable Gastro-Oesophageal and
Pancreatic Cancers - A New Active Regimen [Abstract]
Antitumorigenic
and Antiinsulinogenic Effects of Calcitriol on Insulinoma Cells
and Solid Beta-Cell Tumors [Abstract]
Clinical
Response of an Atypical Glucagonoma Treated with a Long-acting
Somatostatin Analog [Abstract]
Does
Neoadjuvant Chemoradiation Downstage Locally Advanced Pancreatic
Cancer? [Abstract]
Nonfunctioning
Islet Cell Carcinoma of the Pancreas: Case Report [Abstract]
Occlusion
of the Pancreatic Duct versus Pancreaticojejunostomy: A Prospective
Randomized Trial [Abstract]
Preoperative
Endoscopic Stent Placement Before Pancreaticoduodenectomy: A
Meta-Analysis of the Effect on Morbidity and Mortality [Abstract]
|
||
|
For educational
purposes only and not to be relied upon. Please read Pancreatica
Disclaimer |
||
 Home | In The News | Links | Newswire | Donations FAQ | Clinical Trials Database | Research Resources | About Us |
||
|
|
||
|
www.pancreatica.org |
||
